



|  |
| --- |
| **[Enter Report Title]** |
| **[Enter Report Subtitle Identifying the Type of Rapid Review]** |
| **Date of Literature Search:** Click or tap to enter a date.  **Date of Submission:** Click or tap to enter a date. |

|  |
| --- |
| **Prepared By:**  [Click to Enter Author(s) Information]  **Contact:**  [Click to Enter Corresponding Author Information  **Email:**  [Enter Email]  **Suggested citation:** *[Click to provide suggested citation]* |

 

**Funding Acknowledgement(s)**

The SPOR Evidence Alliance ([SPOR EA](http://www.sporevidencealliance.ca)) is supported by the Canadian Institutes of Health Research ([CIHR](http://www.cihr-irsc.gc.ca/e/193.html)) under the Strategy for Patient-Oriented Research ([SPOR](http://www.cihr-irsc.gc.ca/e/41204.html)) initiative.

COVID-19 Evidence Network to support Decision-making ([COVID-END](https://www.mcmasterforum.org/networks/covid-end)) is supported by the Canadian Institutes of Health Research ([CIHR](http://www.cihr-irsc.gc.ca/e/193.html)) through the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding opportunity.

**Project Contributors**

**List full name, affiliation, and role.**

**Third-Party Materials**

If you wish to reuse non-textual material from this report that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is required for such use and to obtain necessary permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned material rests solely with the user.

**General Disclaimer**

This report was prepared by [INSERT INVESTIGATIVE TEAM INFO] on behalf of the SPOR Evidence Alliance and COVID-END. It was developed through the analysis, interpretation and synthesis of scientific research and/or health technology assessments published in peer-reviewed journals, institutional websites and other distribution channels. It also incorporates selected information provided by experts and patient/citizen partners with lived experience on the subject matter. This document may not fully reflect all the scientific evidence available at the time this report was prepared. Other relevant scientific findings may have been reported since completion of this synthesis report.

SPOR Evidence Alliance, COVID-END and the project team make no warranty, express or implied, nor assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, data, product, or process disclosed in this report. Conclusions drawn from, or actions undertaken on the basis of, information included in this report are the sole responsibility of the user.

**Table of Contents**

[Abbreviations and Definitions iii](#_Toc62577470)

[Abbreviations iii](#_Toc62577471)

[Key Definitions: iii](#_Toc62577472)

[EXECUTIVE SUMMARY iv](#_Toc62577473)

[Introduction 1](#_Toc62577474)

[Methods 1](#_Toc62577475)

[Results 1](#_Toc62577476)

[Discussion 2](#_Toc62577477)

[Conclusion 2](#_Toc62577478)

[References 4](#_Toc62577479)

# Abbreviations and Definitions

(This section is optional, but recommended for technical reports.)

### Abbreviations

ABC Text here

DEF Text here

GHI Text here

JKL Text here

MNO Text here

PQR Text here

STU Text here

VWX Text here

YZ Text here

### Key Definitions:

**Word**: Per et graeci verterem, agam fuisset ut vel. Nec argumentum contentiones no, tantas ignota mei te, vis natum legimus te. Usu in enim eros. Pro mutat insolens oportere no, est ne iisque deserunt.

**Word**: Mel quem alienum ne, te eum tation everti. Ut per paulo fierent efficiendi. Per in facilisi necessitatibus. Eu aliquid reprehendunt est. Graeci commune quo ut.

**Word:** In duo quas phaedrum, virtute nonumes posidonium at eam, nec in sint patrioque adversarium. Prompta delicata ne duo. Duo nihil eirmod interpretaris id, ei admodum instructior his. Nusquam blandit ad has. Nisl explicari vix et, in debet vocibus voluptua eum. Ea vim albucius dissentiet, quo veri voluptatibus ne. Et eam porro sadipscing reformidans, mei et deleniti laboramus repudiandae, pro gubergren aliquando no.

# EXECUTIVE SUMMARY

*This should not be longer than 1-2 pages and should include the following:*

***Objectives:*** *A clear statement of the study purpose and research question.*

***Design:*** *Type of rapid review conducted.*

***Method:*** *Brief overview of methods employed.*

***Results:*** *Key findings of the review. Feel free to include graphics here.*

***Conclusion:*** *primary conclusions and their implications, suggest areas for further research if appropriate. Do not go beyond the data in the article.*

***Protocol/Topic Registration:*** *Where applicable, please provide the registration number or link to the protocol/topic.*

|  |  |  |  |
| --- | --- | --- | --- |
| Example 1 | Example 2 | Example 3 | Example 4 |
|  |  |  |  |
|  |  |  |  |

# Introduction

Please provide a background to the research question being studied and rationale for the present study.

Clearly state the research question using the population/problem, interventions/exposure, comparisons, outcomes, study design, and time (PICOST) framework or other relevant key elements used to conceptualize the review question.

# Methods

Where applicable, please provide the protocol or topic registration details and links.

Eligibility Criteria – clearly define the eligibility criteria.

Literature Search – list all sources searched, describe any limitations applied, was a peer-review of the strategy done, date literature search was performed, include full electronic search strategy for at least one database.

Study Selection – State the process for selecting studies (e.g., screening form(s) used, pilot exercise, number of reviewers, etc.).

Data Extraction – Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.

Risk of Bias Assessment (if applicable) – Describe tool uses, methods used for assessing risk of bias of individual studies, and how this information is to be used in any data synthesis.

Data Synthesis – Describe the methods of handling data and combining results.

# Results

Study Selection - Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage. Include a PRISMA flow diagram to show the process.

Study Characteristics - For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.

Risk of bias assessment – Present data on risk of bias of each study in an appendix and also as an aggregate using figures.

Present all thematic and categorical results using tables and figures.

# Discussion

Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups. Also

Discuss the strengths and limitations of the review.

# Conclusion

Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications for health systems decision-making.

**1**

**2**

**1**

# References